Li You-ping, Tao Tie-jun
Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Dec;24(6):548-9.
In the late part of the 20th century, due to the change of disease spectra, rapid increase of health expenditure and imbalanced distribution of health resources, the health management sectors and doctors increasingly demand the scientific decision-making. With the development of clinical evidences and research, evidence-based medicine (EBM) became emerged in the early 1990's. EBM, the medical science in compliance with the best available clinical evidence, integrates clinical epidemiology (CE), systematic reviews (SRs) and health technology assessment (HTA) as the major technology, to emphasize that the clinical practice should be based on the combination of the best available clinical evidence, medical experiences and patient desire to cope with the demand of medical decision-making. Some governments and international organizations like WHO, and Australia have now adopted the high-quality evidence of EBM for decision-making. As the largest developing country, China is challenged by variety of health problems. The introduction, adaptation and implementation of EBM will improve the decision-making and health care services, which should enhance the competitive capacity of medical and pharmaceutical manufactures, as well as promote the popularization of EBM, and protect the doctors and patients rights.
在20世纪后期，由于疾病谱的变化、卫生支出的快速增长以及卫生资源分配不均衡，卫生管理部门和医生对科学决策的需求日益增加。随着临床证据和研究的发展，循证医学于20世纪90年代初应运而生。循证医学是一门遵循最佳可得临床证据的医学科学，它将临床流行病学（CE）、系统评价（SRs）和卫生技术评估（HTA）整合为主要技术，强调临床实践应基于最佳可得临床证据、医学经验和患者意愿的结合，以应对医疗决策的需求。目前，世界卫生组织、澳大利亚等一些政府和国际组织已采用循证医学的高质量证据进行决策。作为最大的发展中国家，中国面临着各种各样的卫生问题。循证医学的引入、适应和实施将改善决策和医疗服务，这将提高医药生产企业的竞争力，促进循证医学的普及，并保护医生和患者的权益。
